Ciclosporin/Omeprazole - Perle Bioscience

Drug Profile

Ciclosporin/Omeprazole - Perle Bioscience

Alternative Names: Omeprazole/ciclosporin - Perle Biosciences; PRL-001

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Perle Bioscience
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antihyperglycaemics; Ciclosporins; Gastric antisecretories; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 1 diabetes mellitus

Most Recent Events

  • 28 Oct 2016 Clinical development is ongoing in Spain (Perle Bioscience pipeline; October 2016)
  • 15 Apr 2016 Perle Bioscience withdraws a clinical trial for Type-1 diabetes mellitus in Spain (EudraCT 2015-000105-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top